Japan’s Nihon Chouzai Sees First Generics Profits Due To Policy Change
This article was originally published in PharmAsia News
Japan’s push toward generic drugs over branded ones has allowed Nihon Chouzai, a chain of pharmacies, to report its first year in the black for the generics portion of its business.
You may also be interested in...
Designed to decrease venous leak from the corpora cavernosa, Giddy makes its Eddie device in oblong shape that opens at one point into two S-forms. Elastic bands are placed around the S-forms to pull the shape together at variable tensions.
Veklury is now the first US FDA-approved treatment for COVID-19, but its limited benefits means its lifespan as a blockbuster could be short.
As negotiations between the UK and EU enter a crucial phase, the UK life sciences industry has called for more clarity and guidance on what companies can expect to face at the end of the Brexit transition period.